<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Cardiothorac Surg</journal-id><journal-id journal-id-type="iso-abbrev">J Cardiothorac Surg</journal-id><journal-title-group><journal-title>Journal of Cardiothoracic Surgery</journal-title></journal-title-group><issn pub-type="epub">1749-8090</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4693888</article-id><article-id pub-id-type="publisher-id">1749-8090-10-S1-A73</article-id><article-id pub-id-type="doi">10.1186/1749-8090-10-S1-A73</article-id><article-categories><subj-group subj-group-type="heading"><subject>Meeting Abstract</subject></subj-group></article-categories><title-group><article-title>Custodiol - N versus Custodiol: a prospective randomized double blind multicenter phase III Trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Szabó</surname><given-names>Gábor</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Weymann</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Schmack</surname><given-names>Bastian</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Badowsky-Zyla</surname><given-names>Dominika</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Veres</surname><given-names>Gábor Gábor</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Wagner</surname><given-names>Florian</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Rastan</surname><given-names>Ardawan</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Doenst</surname><given-names>Thorsten</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Karck</surname><given-names>Matthias</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>University of Heidelberg, Heidelberg, 69120, Germany</aff><aff id="I2"><label>2</label>University of Hamburg, Hamburg, 20251, Germany</aff><aff id="I3"><label>3</label>Heart Center Rotenburg, Rotenburg, 36199, Germany</aff><aff id="I4"><label>4</label>University of Jena, Jena, 07747, Germany</aff><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>16</day><month>12</month><year>2015</year></pub-date><volume>10</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Proceedings of the WSCTS 25th Anniversary Congress</named-content><named-content content-type="supplement-editor">Vipin Zamvar and Leonie Postma</named-content><named-content content-type="supplement-sponsor">Publication charges for this supplement were funded by the WSCTS conference. The Supplement Editors declare no competing interests.</named-content></supplement><fpage>A73</fpage><lpage>A73</lpage><permissions><copyright-statement>Copyright © 2015 Szabó et al.</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Szabó et al.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.cardiothoracicsurgery.org/content/10/S1/A73"></self-uri><conference><conf-date>19-22 September 2015</conf-date><conf-name>World Society of Cardiothoracic Surgeons 25th Anniversary Congress, Edinburgh</conf-name><conf-loc>Edinburgh, UK</conf-loc></conference></article-meta></front><body><sec><title><offsets xml_i="4779" xml_f="4802" txt_i="7" txt_f="30">Background/Introduction</offsets></title><p><offsets xml_i="4813" xml_f="5080" txt_i="31" txt_f="298">HTK-Solution (Custodiol) is a well-established cardioplegic and organ preservation solution. We currently developed a novel HTK based solution Custodiol-N which includes iron chelators to reduce oxidative injury as well as L-arginine, to improve endothelial function.</offsets></p></sec><sec><title><offsets xml_i="5102" xml_f="5117" txt_i="300" txt_f="315">Aims/Objectives</offsets></title><p><offsets xml_i="5128" xml_f="5261" txt_i="316" txt_f="449">In the present first-in-human study, Custodiol-N was compared with Custodiol in patients undergoing elective coronary bypass surgery.</offsets></p></sec><sec><title><offsets xml_i="5283" xml_f="5289" txt_i="451" txt_f="457">Method</offsets></title><p><offsets xml_i="5300" xml_f="5751" txt_i="458" txt_f="906">The study was designed as prospective randomized double blind non-inferiority trial. Primary end-point was area under the curve (AUC) of creatine kinase MB (CKMB) within the first 24 hours after surgery. Secondary endpoints included, peak CKMB and troponin-T and AUC of troponin-T release, cardiac index, cumulative catecholamine dose, ICU-stay and mortality. All values are given as mean ± SD, p &lt; 0.05 was considered as statistically significant.</offsets></p></sec><sec><title><offsets xml_i="5773" xml_f="5780" txt_i="908" txt_f="915">Results</offsets></title><p><offsets xml_i="5791" xml_f="6508" txt_i="916" txt_f="1624">Early termination of the trial was performed per protocol as the primary non-inferiority end point was reached after inclusion of 101 patients. Patient characteristics, medical history, operation and cross-clamp times did not differ between the groups. CKMB AUC (878 ± 549 vs. 778 ± 439 h*U/l, non-inferiority p &lt; 0.001) and Troponin-T AUC (12990 ± 8347 vs. 13498 ± 6513 h*pg/ml, non-inferiority p &lt; 0.001) was similar in both groups. Although the trial was designed for non-inferiority, peak CKMB (52 ± 40 vs. 41 ± 30 U/l, superiority p &lt; 0.002) was significantly lower in the Custodiol-N group. Cardiac index, catecholamines ICU-stay and mortality (1 death in the control group) was similar in both groups.</offsets></p></sec><sec><title><offsets xml_i="6530" xml_f="6551" txt_i="1626" txt_f="1647">Discussion/Conclusion</offsets></title><p><offsets xml_i="6562" xml_f="6862" txt_i="1648" txt_f="1948">This study shows that Custodiol-N is safe and provides similar cardiac protection as the established HTK-Custodiol solution. The significantly reduced peak CKMB levels in the Custodiol-N group may implicate a beneficial effect on ischemia/reperfusion injury in the setting of coronary bypass surgery.</offsets></p></sec></body></article>